Billionaire Larry Robbins’ 10 Stock Picks with Huge Upside Potential

2. Myriad Genetics Inc. (NASDAQ:MYGN)

Glenview Capital’s Stake: $56.99 million

Number of Hedge Fund Holders: 21

Average Upside Potential as of May 8: 87.35%

Myriad Genetics Inc. (NASDAQ:MYGN) is a molecular diagnostic testing and precision medicine company. It offers diagnostic tests for oncology, women’s health, and pharmacogenomics. It has a license collaboration with Illumina, Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, the University of Rochester Medical Center, and Flatiron Health.

Myriad Genetics saw 11% revenue growth in 2024, which was partly driven by its Pharmacogenomics business that is centered around the GeneSight test. In 2024, GeneSight revenues saw an increase of 23% year-over-year, and this demand continued into Q4 with a 14% revenue increase. Myriad is expanding access to GeneSight, despite recent reimbursement challenges with UnitedHealthcare.

It’s focusing on digital engagement to increase provider and patient awareness and optimizing patient direct payment options. Myriad Genetics Inc. (NASDAQ:MYGN) is also encouraged by the momentum of biomarker legislation, which supports access to precision medicine. Furthermore, new clinical data shows that the economic utility of GeneSight is expected to be published in 2025, which could further support its adoption.